NDLI: A prospective study to investigate the role of serial serum mesothelin in monitoring mesothelioma

Content Provider	Springer Nature : BioMed Central
Author	de Fonseka, Duneesha Arnold, David T. Stadon, Louise Morley, Anna Keenan, Emma Darby, Michael Armstrong, Lynne Virgo, Paul Maskell, Nick A.
Abstract	Background Radiological monitoring of malignant pleural mesothelioma (MPM) using modified RECIST criteria is limited by low sensitivity and inter-observer variability. Serial serum mesothelin measurement has shown utility in the assessment of treatment response during chemotherapy but has never been assessed in the longer term follow up of patients. Methods This is a single centre study of consecutive patients diagnosed with MPM who received chemotherapy or best supportive care (BSC). Serum mesothelin measurements with paired 6 monthly CT scans were performed following the completion of chemotherapy, or from baseline in the BSC group. Changes in mesothelin were correlated with radiological progression and overall survival. Results Forty-one patients with MPM were recruited and followed up for a minimum of 12 months (range 12–21 months). The majority of patients (n = 23) received chemotherapy with pemetrexed and cisplatin. Across the cohort a 10% rise in serum mesothelin could predict radiological progression with a sensitivity of 96% (IQR; 79–100) and specificity of 74% (IQR; 50–91). Sensitivity fell to 80% in sarcomatoid only disease. Patients with a rising mesothelin at 6 months had significantly worse overall survival (175 days) compared to stable/falling levels (448 days) (p = 0.003). Conclusions This is the first study to assess serum mesothelin’s ability to detect progression of MPM following chemotherapy or during BSC. A 10% rise in serum mesothelin level showed excellent sensitivity at predicting progressive disease. Mesothelin measurement has several advantages over serial CT imaging including reducing hospital visits and cost.
Related Links	https://bmccancer.biomedcentral.com/counter/pdf/10.1186/s12885-018-4113-3.pdf
Ending Page	7
Page Count	7
Starting Page	1
File Format	HTM / HTML
ISSN	14712407
DOI	10.1186/s12885-018-4113-3
Journal	BMC Cancer
Issue Number	1
Volume Number	18
Language	English
Publisher	BioMed Central
Publisher Date	2018-02-17
Access Restriction	Open
Subject Keyword	Cancer Research Oncology Surgical Oncology Health Promotion and Disease Prevention Biomedicine Medicine Public Health Mesothelioma Mesothelin Biomarkers Monitoring Medicine/Public Health
Content Type	Text
Resource Type	Article
Subject	Cancer Research Oncology Genetics
Journal Impact Factor	3.4/2023
5-Year Journal Impact Factor	3.8/2023

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

A serum mesothelin level is a prognostic indicator for patients with malignant mesothelioma in routine clinical practice

Calretinin as a blood-based biomarker for mesothelioma

Midkine is a potential novel marker for malignant mesothelioma with different prognostic and diagnostic values from mesothelin

Serum HMGB1 as a prognostic marker for malignant pleural mesothelioma

HE4 as a serum biomarker for the diagnosis of pelvic masses: a prospective, multicenter study in 965 patients

Searching for early breast cancer biomarkers by serum protein profiling of pre-diagnostic serum; a nested case-control study

Serum levels of the chemokine CCL2 are elevated in malignant pleural mesothelioma patients

Exploring RNA cargo in extracellular vesicles for pleural mesothelioma detection

Utilizing serum metabolomics for assessing postoperative efficacy and monitoring recurrence in gastric cancer patients

A prospective study to investigate the role of serial serum mesothelin in monitoring mesothelioma

Similar Documents

A serum mesothelin level is a prognostic indicator for patients with malignant mesothelioma in routine clinical practice

Calretinin as a blood-based biomarker for mesothelioma

Midkine is a potential novel marker for malignant mesothelioma with different prognostic and diagnostic values from mesothelin

Serum HMGB1 as a prognostic marker for malignant pleural mesothelioma

HE4 as a serum biomarker for the diagnosis of pelvic masses: a prospective, multicenter study in 965 patients

Searching for early breast cancer biomarkers by serum protein profiling of pre-diagnostic serum; a nested case-control study

Serum levels of the chemokine CCL2 are elevated in malignant pleural mesothelioma patients

Exploring RNA cargo in extracellular vesicles for pleural mesothelioma detection

Utilizing serum metabolomics for assessing postoperative efficacy and monitoring recurrence in gastric cancer patients

A prospective study to investigate the role of serial serum mesothelin in monitoring mesothelioma